Skip to main content
. Author manuscript; available in PMC: 2011 Aug 15.
Published in final edited form as: J Infect Dis. 2010 Aug 15;202(4):595–605. doi: 10.1086/654816

Fig. 5.

Fig. 5

Comparison of pre-infection NAb responses in vaccine recipients to post-infection NAb responses in placebo recipients. Plasma from 90 vaccine recipients (2 weeks post fourth inoculation) and 14 placebo recipients (1–2 years post diagnosis) were assayed against MN, SF162.LS and the subtype B reference panel of tier 2 viruses. A. TZM-bl assay. B. U87.CD4.CCR5.CXCR4 assay. Subject-specific and group averages in M-B plots are shown as light and heavy lines, respectively, and are for the tier 2 viruses only.